pexidartinib

Drug Overview

Pexidartinib is a specialized medication used to treat rare tumors that grow in the joints. It is known as a Targeted Therapy because it focuses on blocking specific proteins that cause tumors to grow. Unlike general treatments, this “Smart Drug” aims at the root cause of the tumor at a cellular level.

• Generic Name: Pexidartinib
• US Brand Names: Turalio®
• Drug Class: Kinase Inhibitor; Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitor
• Route of Administration: Oral (Capsule)
• FDA Approval Status: FDA Approved (Approved in August 2019)
  
  Find expert information on pexidartinib for specific tumor types. Trust our leading medical hospital for specialized and effective patient care.

What Is It and How Does It Work? (Mechanism of Action)

Pexidartinib is a small-molecule tyrosine kinase inhibitor. Its primary job is to “shut off” signals that tell tumor cells to multiply. To understand how it works at the molecular level, we look at specific receptors on the surface of cells:

Blocking the CSF-1 Receptor

In the rare tumors pexidartinib treats, the body produces too much of a protein called Colony-Stimulating Factor 1 (CSF-1). This protein binds to a “mailbox” on the cell surface called the CSF-1 Receptor (CSF-1R).

When this receptor is activated, it sends a constant signal through internal pathways (like the MAPK/ERK pathway) that tells cells to grow uncontrollably and causes inflammation in the joint. Pexidartinib acts like a key that gets stuck in the lock of the CSF-1R mailbox. By blocking this receptor, the drug:

• Interrupts the growth signal.
• Reduces the number of abnormal cells in the joint lining (synovium).
• Decreases the painful inflammation that damages the bone and joint.

Multi-Targeted Action

While its main target is CSF-1R, pexidartinib also blocks other receptors like KIT and FLT3. By targeting multiple pathways at once, the drug provides a robust defense against the tumor’s survival.

FDA Approved Clinical Indications

Pexidartinib is approved for a very specific use where surgery is not an option.

Oncological Uses:

• Tenosynovial Giant Cell Tumor (TGCT): Used in adult patients with symptomatic TGCT (also known as pigmented villonodular synovitis or PVNS). It is prescribed when the tumor is causing severe pain or physical limitations and cannot be improved by surgery.

Non-oncological Uses:

• None.

Dosage and Administration Protocols

Pexidartinib must be taken with a low-fat meal to ensure the drug is absorbed correctly and safely.

Dose Adjustments

• Renal (Kidney) Insufficiency: For mild to severe kidney impairment, the dose is typically reduced (e.g., 125 mg in the morning and 250 mg in the evening).
• Hepatic (Liver) Insufficiency: * Mild: No adjustment needed.
  • Moderate: Dose is reduced (e.g., 125 mg twice daily).
  • Severe: Not recommended, as the drug has not been studied in this group.

Clinical Efficacy and Research Results

The effectiveness of pexidartinib was proven in the ENLIVEN study, the first large trial for this type of tumor.

• Tumor Response: In the study, 38% of patients taking pexidartinib saw their tumors shrink significantly by Week 25, compared to 0% in the group taking a placebo.
• Long-Term Benefit: Follow-up data through 2021–2025 shows that for patients who respond, the benefit lasts. Recent results indicate an Overall Response Rate (ORR) of up to 60% when patients are followed for 3 years or more.
• Physical Improvement: Patients reported significantly less joint stiffness and a better range of motion, allowing them to return to daily activities they previously could not perform.

Safety Profile and Side Effects

Black Box Warning

WARNING: RISK OF SERIOUS LIVER INJURY

Pexidartinib can cause serious and potentially fatal liver damage. Due to this risk, it is only available through a restricted program called the Turalio REMS Program. Doctors must monitor liver tests weekly for the first 8 weeks of treatment.

Common Side Effects (>10%)

• Hair Color Changes: Hair may turn white or gray during treatment.
• Fatigue: Feeling unusually tired.
• Altered Taste: A change in how food tastes (dysgeusia).
• Lab Changes: Increased cholesterol levels and increased liver enzymes (AST/ALT).
• Eye Problems: Swelling around the eyes (periorbital edema).

Serious Adverse Events

• Severe Hepatotoxicity: Life-threatening liver failure or “Vanishing Bile Duct Syndrome.”
• Embryo-Fetal Toxicity: Can cause severe harm to an unborn baby.

Management Strategies

• Liver Monitoring: If liver tests become too high, the drug must be paused or stopped entirely.
• Dietary Control: Avoid high-fat meals, as they can double the amount of drug in your blood and increase liver risk.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, pexidartinib is being studied for its ability to change the “environment” around a tumor. Researchers are testing if pexidartinib can clear out “bad” immune cells (macrophages) that protect cancer from the immune system. Current clinical trials are looking at combining pexidartinib with Immune Checkpoint Inhibitors (like PD-1 blockers) to see if this combination can shrink difficult tumors like colorectal or lung cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Liver Function Panel: Must be performed before the first dose.
• Pregnancy Test: Required for women who can become pregnant.
• Lipid Panel: To check cholesterol levels.

“Do’s and Don’ts”

• DO take capsules whole; do not crush or chew them.
• DO use effective, non-hormonal birth control during treatment.
• DO stay out of the sun or wear protective clothing, as the drug makes skin sensitive to light.
• DON’T eat grapefruit or drink grapefruit juice, as it interacts with the medication.
• DON’T take “Proton Pump Inhibitors” (like Omeprazole) without talking to your doctor, as they can stop the drug from working.

Legal Disclaimer

Standard Medical Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Pexidartinib (Turalio®) is a powerful medication that requires strict medical supervision. Always consult with your oncologist or healthcare provider before starting or changing any medical treatment.